AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer
A phase 1/2 trial of Ivonescimab, Cadonilimab, Carboplatin in non-small-cell lung cancer and small-cell lung cancer, run by Akeso, active and no longer recruiting.
Overview
AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer is a phase 1/2 interventional study registered as NCT05904379 by Akeso, with 233 participants planned, started 2023-07-13 and due to reach its primary completion in 2026-06-30. Interventions recorded: AK112, AK104, Carboplatin, paclitaxel, pemetrexed. Conditions listed: Advanced Non-small-cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialAK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC
Shares Ivonescimab, Akeso, Paclitaxel / nab-paclitaxel, Carboplatin.
- TrialIvonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer
Shares Ivonescimab, Akeso, Docetaxel, Small-cell lung cancer.
- TrialAK129 Combination Therapy for Advanced Solid Tumors
Shares Akeso, Docetaxel, Pemetrexed, Paclitaxel / nab-paclitaxel.
- TrialA Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Non-Small Cell Lung Cancer
Shares Ivonescimab, Akeso, Carboplatin, Small-cell lung cancer.
- TrialAK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer
Shares Ivonescimab, Akeso, Carboplatin, Small-cell lung cancer.
- TrialA Study of Ivonescimab in First-Line ES-SCLC
Shares Cadonilimab, Ivonescimab, Akeso, Carboplatin.
- TrialAK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer
Shares Cadonilimab, Ivonescimab, Akeso, Paclitaxel / nab-paclitaxel.
- TrialIPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Carboplatin, Small-cell lung cancer.